The use of an interleukin 1 inhibitor in a patient with atypical course of periodic fever

The article presents a case of periodic fever (PF) in a 35-year-old patient, who did not have hereditary and proven genetic factors of the disease, which was characterized by an atypical course with variable in duration and frequency severe abdominal pain and febrile fever attacks, increased acute phase reactants and ineffectiveness of colchicine intake. Differential diagnosis with a wide range of febrile conditions was performed. Daily subcutaneous therapy of interleukin 1 inhibitor (iIL1) at a dose of 100 mg was used as a diagnostic marker to confirm the diagnosis of PF. As a result of the therapy, a rapid (within a few hours after injection) relief of the current attack of the disease, normalization of serum CRP levels, and further complete control over the disease (no relapses) were achieved. Our observation shows that a positive response to iIL1 therapy can serve as a diagnostic marker of PF.

1. Milhavet F, Cuisset L, Hoffman HM, et al. The infevers autoinflammatory mutation online registry: update with new genes and functions. Hum Mutat. 2008 Jun;29(6):803-8. doi: 10.1002/humu.20720.

2. Salugina SO, Fedorov ES, Kuz'mina NN. Current approaches to diagnosis, treatment, and monitoring in patients with cryopyrinassociated periodic syndromes (CAPS). Sovremennaya revmatologiya = Modern Rheumatology Journal. 2016;10(2):4-11. (In Russ.). doi: 10.14412/1996-7012-2016-2-4-11.

3. Lalaoui N, Boyden SE, Oda H, et al. Mutations that prevent caspase cleavage of RIPK1 cause autoinflammatory disease. Nature. 2020 Jan;577(7788):103-8. doi: 10.1038/s41586-019-1828-5. Epub 2019 Dec 11.

4. Drenth JP, van der Meer JW. Hereditary periodic fever. N Engl J Med. 2001 Dec 13; 345(24):1748-57. doi: 10.1056/NEJMra010200.

5. Federici S, Sormani MP, Ozen S, et al. Evidence-based provisional clinical classification criteria for autoinflammatory periodic fevers. Ann Rheum Dis. 2015 May;74(5):799-805. doi: 10.1136/annrheumdis-2014-206580. Epub 2015 Jan 30.

6. Yalcinkaya F, Ozen S, Ozcakar ZB, et al. A new set of criteria for the diagnosis of familial Mediterranean fever in childhood. Rheumatology (Oxford). 2009 Apr;48(4): 395-8. doi: 10.1093/rheumatology/ken509. Epub 2009 Feb 4.

7. Soon GS, Laxer RM. Approach to recurrent fever in childhood. Can Fam Physician. 2017 Oct;63(10):756-762.

8. Kucuk A, Gezer IA, Ucar R, Karahan AY. Familial Mediterranean Fever. Acta Medica (Hradec Kralove). 2014;57(3):97-104. doi: 10.14712/18059694.2014.47.

9. Ter Haar NM, Oswald M, Jeyaratnam J, et al. Recommendations for the management of autoinflammatory diseases. Ann Rheum Dis. 2015 Sep;74(9):1636-44. doi: 10.1136/annrheumdis-2015-207546. Epub 2015 Jun 24.

10. Harrison SR, McGonagle D, Nizam S, et al. Anakinra as a diagnostic challenge and treatment option for systemic autoinflammatory disorders of undefined etiology. JCI Insight. 2016 May 5;1(6):e86336. doi: 10.1172/jci.insight.86336.

11. Ozen S, Kuemmerle-Deschner JB, Cimaz R, et al. International Retrospective Chart Review of Treatment Patterns in Severe Familial Mediterranean Fever, Tumor Necrosis Factor Receptor-Associated Periodic Syndrome, and Mevalonate Kinase Deficiency/Hyperimmunoglobulinemia D Syndrome. Arthritis Care Res (Hoboken). 2017 Apr;69(4):578-86. doi: 10.1002/acr.23120. Epub 2017 Mar 3.

12. Ozen S, Kone-Paut I, Gü l A. Colchicine resistance and intolerance in familial mediterranean fever: Definition, causes, and alternative treatments. Semin Arthritis Rheum. 2017 Aug;47(1):115-20. doi: 10.1016/j.semarthrit.2017.03.006. Epub 2017 Mar 20.

13. http://fmf.igh.cnrs.fr/infevers/.

14. Giancane G, Ter Haar NM, Wulffraat N, et al. Evidence-based recommendations for genetic diagnosis of familial Mediterranean fever. Ann Rheum Dis. 2015 Apr;74(4):635-41. doi: 10.1136/annrheumdis-2014-206844. Epub 2015 Jan 27.

15. Marek-Yagel D, Berkun Y, Padeh S, et al. Clinical disease among patients heterozygous for familial Mediterranean fever. Arthritis Rheum. 2009 Jun;60(6):1862-6. doi: 10.1002/art.24570.

16. Ben-Chetrit E1, Touitou I. Familial mediterranean Fever in the world. Arthritis Rheum. 2009 Oct 15;61(10):1447-53. doi: 10.1002/art.24458.

17. Ben-Chetrit E, Ozdogan H. Nonresponse to colchicine in FMF — definition, causes and suggested solutions. Clin Exp Rheumatol. Jul-Aug 2008;26(4 Suppl 50): S49-51.

18. Ben-Zvi I, Kukuy O, Giat E, et al. Anakinra for Colchicine-Resistant Familial Mediterranean Fever: A Randomized, Double-Blind, Placebo-Controlled Trial. Arthritis Rheumatol. 2017 Apr;69(4):854-62. doi: 10.1002/art.39995.

19. Gü l A, Ozdogan H, Erer B, et al. Efficacy and safety of canakinumab in adolescents and adults with colchicine-resistant familial Mediterranean fever. Arthritis Res Ther. 2015 Sep 4;17(1):243. doi: 10.1186/s13075-015-0765-4.

20. Sahin A, Derin ME, Albayrak F, et al. Assessment of effectiveness of anakinra and canakinumab in patients with colchicineresistant/ unresponsive familial Mediterranean fever. Adv Rheumatol. 2020 Jan 30;60(1):12. doi: 10.1186/s42358-020-0117-1.

21. Harrison SR, McGonagle D, Nizam S, et al. Anakinra as a diagnostic challenge and treatment option for systemic autoinflammatory disorders of undefined etiology. JCI Insight. 2016 May 5;1(6):e86336. doi: 10.1172/jci.insight.86336.

22. Hentgen V, Vinit C, Fayand A, Georgin- Lavialle S. The Use of Interleukine-1 Inhibitors in Familial Mediterranean Fever Patients: A Narrative Review. Front Immunol. 2020 May 28;11:971. doi: 10.3389/fimmu.2020.00971. eCollection 2020.